Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access to treatments for long covid.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to ensuring that families have the support that they need. The Care Act 2014 requires local authorities to deliver a wide range of sustainable, high-quality care and support services, including support for carers, which can include parents.
Across the National Health Service in England, there are services supporting people with post-COVID syndrome, often described as long COVID. These services offer physical, cognitive, and psychological assessment, and, where appropriate, refer patients onto existing services for treatment and rehabilitation. Further information can be found via the NHS website, at the following link:
https://www.england.nhs.uk/coronavirus/post-covid-syndrome-long-covid/
The National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) remain committed to funding high-quality research to understand the causes, consequences, and treatment for long COVID. We are actively exploring next steps for research in this area.
Between 2019/20 and 2023/24, through the NIHR and MRC, we have invested over £57 million on research into long COVID, with almost £40 million of this through two specific research calls on long COVID. The funded projects aim to improve our understanding of the diagnosis and underlying mechanisms of the disease and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate the effectiveness of clinical care.
This includes funded clinical trials to test and compare different treatments such as antihistamines, anticoagulants, and anti-inflammatory medicines, as well as trials such as the approximately £1.5 million REGAIN trial funded through the NIHR. REGAIN is the first randomised trial to show a benefit from rehabilitation for people with long COVID, and the first high-quality evidence confirming the sustained clinical benefit and lack of harm with rehabilitation programmes for long COVID which combine exercise with behavioural support, to measure their effects on symptoms, health, and other outcomes.
The approximately £1.9 million CLoCk study, co-funded by the NIHR and the MRC, developed an agreed definition of long COVID in children and young people as well as the associated symptoms, which will help harmonise research and improve understanding of the condition.
Funding is available and we welcome funding applications for research into long COVID in both adults and children. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
To support clinical leadership in this area, NHS England has worked in partnership with the British Society of Physical and Rehabilitation Medicine to develop a new Clinical Post-COVID Society to facilitate the ongoing sharing of best practice and to support people affected by long COVID. Further information about the society can be found at the following link:
https://www.clinicalpcs.org.uk
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of clinical research into treatments for long covid.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to ensuring that families have the support that they need. The Care Act 2014 requires local authorities to deliver a wide range of sustainable, high-quality care and support services, including support for carers, which can include parents.
Across the National Health Service in England, there are services supporting people with post-COVID syndrome, often described as long COVID. These services offer physical, cognitive, and psychological assessment, and, where appropriate, refer patients onto existing services for treatment and rehabilitation. Further information can be found via the NHS website, at the following link:
https://www.england.nhs.uk/coronavirus/post-covid-syndrome-long-covid/
The National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) remain committed to funding high-quality research to understand the causes, consequences, and treatment for long COVID. We are actively exploring next steps for research in this area.
Between 2019/20 and 2023/24, through the NIHR and MRC, we have invested over £57 million on research into long COVID, with almost £40 million of this through two specific research calls on long COVID. The funded projects aim to improve our understanding of the diagnosis and underlying mechanisms of the disease and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate the effectiveness of clinical care.
This includes funded clinical trials to test and compare different treatments such as antihistamines, anticoagulants, and anti-inflammatory medicines, as well as trials such as the approximately £1.5 million REGAIN trial funded through the NIHR. REGAIN is the first randomised trial to show a benefit from rehabilitation for people with long COVID, and the first high-quality evidence confirming the sustained clinical benefit and lack of harm with rehabilitation programmes for long COVID which combine exercise with behavioural support, to measure their effects on symptoms, health, and other outcomes.
The approximately £1.9 million CLoCk study, co-funded by the NIHR and the MRC, developed an agreed definition of long COVID in children and young people as well as the associated symptoms, which will help harmonise research and improve understanding of the condition.
Funding is available and we welcome funding applications for research into long COVID in both adults and children. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
To support clinical leadership in this area, NHS England has worked in partnership with the British Society of Physical and Rehabilitation Medicine to develop a new Clinical Post-COVID Society to facilitate the ongoing sharing of best practice and to support people affected by long COVID. Further information about the society can be found at the following link:
https://www.clinicalpcs.org.uk
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve the treatments available for brain tumours in west London.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government has invested in new lifesaving and life-improving research, supporting those diagnosed and living with brain tumours. In September 2024, the National Institute for Health and Care Research (NIHR) announced new research funding opportunities for brain cancer research, spanning both adult and paediatric populations. This includes a national NIHR Brain Tumour Research Consortium, to ensure the most promising research opportunities are made available to adult and child patients.
The National Cancer Plan will include further details on how we will improve outcomes, including treatment options, for all cancer patients including those with brain tumours.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he has taken to increase the availability of assessments for ADHD in West London.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
It is the responsibility of the integrated care boards (ICBs) in England to make appropriate provision to meet the health and care needs of their local population, including assessments for attention deficit hyperactivity disorder (ADHD), in line with relevant National Institute for Health and Care Excellence guidelines.
NHS England has established an ADHD taskforce which is working to bring together those with lived experience, experts from the National Health Service, education, charity, and justice sectors. The taskforce is working to get a better understanding of the challenges affecting those with ADHD, including timely and equitable access to services and support, with the final report expected in the summer of 2025.
In conjunction with the taskforce, NHS England has carried out detailed work to develop an ADHD data improvement plan to inform future service planning. NHS England has also conducted detailed work to understand the provider and commissioning landscape, capturing examples from ICBs who are trialling innovative ways of delivering ADHD services. NHS England is using this information to support systems to tackle ADHD waiting lists and provide support to address people’s needs.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he is taking steps to introduce early diagnosis services for osteoporosis.
Answered by Andrew Gwynne
Funding was recently announced to boost bone density scanning capacity, to support improvements in bone health and early diagnostics for musculoskeletal (MSK) conditions, such as osteoporosis. This will provide an estimated 29,000 extra scans per year.
As announced in the Get Britain Working white paper, we are delivering the joint Department for Work and Pensions, Department of Health and Social Care, and NHS England’s Getting It Right First-Time (GIRFT) MSK Community Delivery Programme. With a £3.5 million funding boost, GIRFT teams will deploy their proven Further Faster model to work with integrated care board leaders to further reduce MSK community waiting times, including for those with osteoporosis, and improve data, metrics, and referral pathways to wider support services.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of HRT products in London.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department monitors and manages medicine supply at a national level so that stocks remain available to meet regional and local demand. Information on stock levels within London is not held centrally.
There are over 70 hormone replacement therapy (HRT) products, and the vast majority are in good supply. Previously there has been issues with the supply of a limited number of these products, primarily driven by very sharp increases in demand. Following the Department’s intensive engagement with industry, the supply position has improved considerably. As part of this we have met with suppliers on a very regular basis and have held seven HRT supply roundtables since April 2022, with the most recent in September 2024, with suppliers, wholesalers, and community pharmacists, to provide updates on the supply position and actions being taken to address them, to share data, and to discuss relevant policy developments and potential impacts.
We are aware of the supply issues affecting Estradot (estradiol) 50 microgram/24 hour, 75 microgram/24 hour, and 100 microgram/24 hour patches, for which we have issued comprehensive management guidance to the National Health Service, including Serious Shortage Protocols allowing community pharmacists to supply the equivalent strength patch of an alternative brand without the need for a new prescription. Alternative brands of estradiol patches remain available.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether applications for the NHS and Social Care Coronavirus Life Assurance payment received after 30 September 2023 are eligible.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The NHS and Social Care Coronavirus Life Assurance Scheme was launched on 20 May 2020 to recognise the increased risks that National Health Service and social care staff faced in carrying out their duties during the coronavirus pandemic.
The Scheme closed to new deaths on 31 March 2022. Under the rules of the scheme, claimants were required to submit claims for deaths that occurred while the Scheme was open before 30 September 2023.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the (a) recruitment and (b) retention of radiologists in London.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
National Health Service organisations in London will have their own plans in place to manage their recruitment and retention needs, based on local workforce planning.
A clear plan for retention is an essential component of an overall supply plan for the NHS. We need to retain the experienced and skilled staff that we already have, and ensure that the NHS is an attractive place to work so that we can bring in the new trainees and recruits that we need. Nationally, the NHS retention programme is working with NHS organisations to improve culture and leadership across the NHS, addressing issues that matter to staff, such as the need for good occupational health and wellbeing support and the promotion of opportunities to work flexibly.
We have launched a 10-Year Health Plan to reform the NHS. A central and core part of the 10-Year Health Plan will be our workforce, and how we ensure we train and provide the staff, technology, and infrastructure the NHS needs to care for patients when and where they need it.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential health benefits of magnesium supplements.
Answered by Andrew Gwynne
The Government’s nutrition advice is based on recommendations from the Scientific Advisory Committee on Nutrition (SACN) and its predecessor, the Committee on Medical Aspects of Food and Nutritional Policy (COMA).
The COMA set dietary reference values for magnesium for men and women aged 19 to 64 years old at 300 milligrams and 270 milligrams a day, respectively. Current Government advice is that individuals should be able to get all the magnesium they need by eating a varied and balanced diet.
The SACN discussed the topic of magnesium as part of its horizon scanning in 2020, 2022, and 2024. Meeting papers are available on the SACN webpage. The committee has noted that while ‘significant proportions of the population had [low intakes], there was limited evidence that this was of public health concern’. There is no agreed biomarker for measuring magnesium status.
Magnesium is therefore on the SACN’s watching brief as a low priority, and the SACN may consider it again in future, if there are any developments regarding biomarkers for magnesium status, to warrant a review of recommendations.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what representations she has made to NICE on the availability of Enhertu.
Answered by Andrew Stephenson
The Department meets regularly with the National Institute for Health and Care Excellence (NICE) to discuss a range of issues, including access to medicines. The NICE has recommended Enhertu, also known as trastuzumab deruxtecan and made by Daiichi Sankyo, for use through the Cancer Drugs Fund, for the treatment of HER2-positive metastatic or unresectable breast cancer. It is available to eligible National Health Service patients in England, in line with the NICE’s recommendations.
The NICE is currently evaluating Enhertu for the treatment of HER2-low metastatic or unresectable breast cancer. Following negotiations between NHS England and the company, which concluded without a commercial agreement to make it available at a cost-effective price for the NHS, the NICE published final draft guidance on 5 March 2024, that does not recommend it as an option for this indication. The NICE remains open to further discussions with NHS England and the company, and currently expects to publish final guidance on 15 May 2024.